This study kinda looks like an advertisement but it mentions phase 1 and phase 2 trials like Lindell mentioned in the article.Cooper lying?
October 29, 2019 01:40 PM Eastern Daylight Time
SAN ANTONIO(BUSINESS WIRE)A new research study recently published as an “In Press” article in the Journal of Antivirals & Antiretrovirals (www.longdom.org/antivirals-antiretrovirals.html) [Volume 11, Issue 3, 2019] concludes that “phytomedical compounds,such as the cardenolide oleandrin, may one day represent a cost-effective therapeutic strategy to help combat enveloped virus infections (such as HTLV-1) in developing countries with limited access to modern antivirals.”
The study is the latest in a string of published research papers which speak to various potential uses of oleandrin, an extract from the common Nerium oleander plant, in disease treatments. Oleandrin is the key bioactive component of PBI-05204, a drug developed by Phoenix Biotechnology, Inc. (www.phoenixbiotechnology.com), of San Antonio, TX.
According to Robert A. Newman, PhD, President and Chief Science Officer of Phoenix Biotech, PBI-05204 is the only botanical drug that contains oleandrin which has gone through both Phase I and Phase II clinical trials and is currently under development.
The article is entitled “The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 (HTLV-1) Infectivity and Env-Dependent Virological Synapse Formation.” Authors include Tetiana Hutchison, Lacin Yapindi, Aditi Malu and Robert Harrod (all with the Laboratory of Molecular Virology, Department of Biological Sciences in the Dedman College Center for Drug Discovery, Design & Delivery at Southern Methodist University), Robert A. Newman (previously with the Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center) and K. Jagannadha Sastry (Departments of Immunology and Veterinary Sciences, University of Texas M.D. Anderson Cancer Center). It is an open access article, freely available online.
https://www.businesswire.com/news/home/20191029005927/en/New-Research-Study-Points-Potential-Oleandrin-Therapeutic
PB
>>10335033 , >>10335262 , >>10335343 Diggz on Oleandrin drug